

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy⦠read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
$8.02
Price-0.50%
-$0.04
$789.566m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$0.00
-
1y CAGR-
3y CAGR-25.0%
5y CAGR-$191.780m
-10.0%
1y CAGR-26.6%
3y CAGR-22.8%
5y CAGR-$1.95
+2.0%
1y CAGR+24.5%
3y CAGR+31.5%
5y CAGR$374.132m
$422.893m
Assets$48.761m
Liabilities$20.666m
Debt4.9%
-0.1x
Debt to EBITDA-$172.861m
-9.8%
1y CAGR-23.8%
3y CAGR-16.5%
5y CAGR